Drug Patent List
First Filer Exclusivity TimelineNew
Newsletter
Weekly Digest

Pharsight

Bristol-myers Squibb Drug Patent Portfolio

Bristol-myers Squibb's Family Patents


Family Patents





Clinical Trials

Recent Clinical Trials by Bristol-myers Squibb:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer Bristol-Myers Squibb NA COMPLETED
(Sep 1, 2026)
PHASE3
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) Bristol-Myers Squibb NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma Bristol-Myers Squibb NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) Bristol-Myers Squibb NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) Juno Therapeutics, Inc., a Bristol-Myers Squibb Company NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). Bristol-Myers Squibb NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) Bristol-Myers Squibb NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis Bristol-Myers Squibb NA RECRUITING
(Sep 1, 2026)
PHASE3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) Bristol-Myers Squibb NA RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) Bristol-Myers Squibb NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) Bristol-Myers Squibb NA RECRUITING
(Sep 1, 2026)
PHASE2
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers Bristol-Myers Squibb NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis Bristol-Myers Squibb NA COMPLETED
(Aug 1, 2026)
PHASE3
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis Bristol-Myers Squibb NA RECRUITING
(Aug 1, 2026)
PHASE3
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors Bristol-Myers Squibb NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment Bristol-Myers Squibb NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs Bristol-Myers Squibb NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer Bristol-Myers Squibb NA TERMINATED
(Aug 1, 2026)
PHASE3
A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Bristol-Myers Squibb NA TERMINATED
(Aug 1, 2026)
PHASE3
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis Bristol-Myers Squibb NA RECRUITING
(Aug 1, 2026)
PHASE3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) Bristol-Myers Squibb NA RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3
A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion Bristol-Myers Squibb NA RECRUITING
(Jun 1, 2026)
PHASE1
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) Bristol-Myers Squibb NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2, PHASE3
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Bristol-Myers Squibb NA COMPLETED
(May 1, 2026)
PHASE2
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer Bristol-Myers Squibb NA COMPLETED
(May 1, 2026)
PHASE2
A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants Bristol-Myers Squibb NA COMPLETED
(May 1, 2026)
PHASE1
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission Bristol-Myers Squibb NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Bristol-Myers Squibb NA RECRUITING
(Apr 1, 2026)
PHASE1
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma Juno Therapeutics, Inc., a Bristol-Myers Squibb Company NA WITHDRAWN
(Mar 1, 2026)
PHASE3
Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants Bristol-Myers Squibb NA COMPLETED
(Mar 1, 2026)
PHASE1


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Bristol-myers Squibb News

Is Bristol-Myers Squibb's (US0897961004) leadership in oncology robust?

20 Apr, 2026

Bristol-Myers Squibb's stock: Does its cancer treatment pipeline have the potential to drive growth?

20 Apr, 2026

Is the oncology pipeline robust for Bristol-Myers Squibb Company (US0897961004)?

17 Apr, 2026

The significance of Bristol-Myers Squibb Company's (US0897961004) leadership in oncology.

14 Apr, 2026

See More